key: cord-0014734-s3kxqsnk authors: Clark, Joseph; Gnanapragasam, Sam; Greenley, Sarah; Pearce, Jessica; Johnson, Miriam title: Perceptions and experiences of laws and regulations governing access to opioids in South, Southeast, East and Central Asia: A systematic review, critical interpretative synthesis and development of a conceptual framework date: 2020-10-29 journal: Palliat Med DOI: 10.1177/0269216320966505 sha: c650418985b7a250a849b8e79a64b85599785403 doc_id: 14734 cord_uid: s3kxqsnk BACKGROUND: Opioids are essential medicines. Despite international and national laws permitting availability, opioid access remains inadequate, particularly in South, Southeast, East and Central Asia. AIM: To review evidence of perceptions and experiences of regulatory enablers and barriers to opioid access in South, Southeast, East and Central Asia. DESIGN: Systematic review of post-2000 research according to PRISMA guidelines. Data were subjected to critical interpretive synthesis. International, national and sub-national barriers were organised developing a conceptual framework of opioid availability. DATA SOURCES: PsycINFO, Medline, Embase, The Cochrane Library. CINAHL, Complete and ASSIA from 2000 until 20th May 2019. RESULTS: 21/14097 studies included: quantitative n = 15, qualitative n = 3 and mixed-methods n = 3. Four barrier/enabler themes were developed: Legal, regulatory, socio-political; lack of laws explicitly enabling opioid access, restrictive international controls and clinician prescribing concerns. Opioid availability; limited availability, poor policymaker and clinician education regarding opioid benefits, poor continuity of supply. Opioid Accessibility; medicine costs, distance to prescribing centres. Prescribing; extensive bureaucratic barriers, lack of human resources for prescribing. We present a novel framework of a self-perpetuating model of inadequate opioid provision. The Single Convention on Narcotics provides the context of restrictive laws and negative attitudes amongst policymakers. A consequent lack of prescribers and clinicians’ negative attitudes at sub-national levels, results in inadequate access to and use of opioids. Data of inadequate consumption informs annual requirement estimates used by the International Narcotics Control Board to determine future opioid availability. CONCLUSIONS: Regulatory and socio-political actions unintentionally limit opioid access. International and national laws explicitly enabling opioid access are required, to assuage concerns, promote training and appropriate prescribing. Globally, access to opioid treatments is inadequate. 1 It is estimated that currently 61 million people who need opioids suffer due to lack of access, with the greatest unmet need in low and middle-income countries in South, Southeast, East and Central Asia. 2 Therapeutic opioids are a key aspect of the World Health Organization's (WHO) widely-used three-step cancer pain ladder. 3 Opioids also are indicated for moderate to severe pain in common clinical scenarios such as childbirth, 4 acute musculoskeletal pain, 5 trauma, 6 peri-operative care 7 and, in low doses, for severe chronic breathlessness. 8 Without appropriate access to opioids, physical and associated psychological suffering is severe. Untreated pain also has socio-economic consequences for families, for example, risk of poverty due to inability to work. 9 Suffering incurred by those with unmanaged pain has led to calls for access to pain relief to be a basic human right. 10 Most therapeutic opioids are controlled substances, regulated under international law. Production and distribution of controlled substances (e.g. Morphine) is subject to the terms of the Single Convention on Narcotics and subsequent international drug laws. 11 Weaker opioids (e.g. Tramadol) recommended for Step 2 on the WHO pain ladder, are not internationally controlled substances and are regulated differentially at the national level. The Single Convention on Narcotics has been in force since 1960 to prohibit production and supply of illegal narcotics and ensure access to opioids (narcotic formulations) for medical purposes. Nation states enact drug laws to implement the terms of the Convention. Yet, barriers to access to opioids medicines exist at international, national and sub-national levels. 12 The Lancet Commission on Global Access to Palliative Care and Pain Relief reports that "In most [low and middle-income countries], unduly restrictive laws and regulations hinder the availability of and access to opioids for people with legitimate needs." 2 In the context of laws and regulations which technically permit opioid availability, little is known regarding how laws and regulations interact between levels, to practically enable or limit access to opioids for patients with legitimate medical need. Of concern, the President of the International Narcotics Control Board, the international organisation charged with overseeing the implementation of the Single Convention worldwide, recently questioned the current utility of the Single Convention, first drawn up half a century ago: "I think it is an appropriate time to look at whether those are still fit for purpose, or whether we need new alternative instruments and alternative approaches to deal with these problems [Cornelis P. de Joncheere, 2020]." 13 As the most populous world region, most unmet need for opioids is in South, Southeast, East and Central Asia. We conducted a mixed-methods systematic review of the academic literature to explore perceptions and experiences of regulatory barriers and enablers to opioid access in South, Southeast, East and Central Asia in the context of international and national drug regulations. We aimed to review and synthesise published evidence of perceptions and experiences of regulatory enablers and barriers to opioid access in South, Southeast, East and Central Asia. We conducted a systematic review with critical interpretive synthesis of post-2000 research relevant to our aim with reference to 2009 Centre for Reviews and Dissemination (CRD) guidance for undertaking reviews in healthcare. 14 The review was reported in accordance with recommendations What this paper adds? • • We show how barriers at international level raise further barriers at national and sub-national levels which limit accessibility of opioids, even when they are technically available. • • The international opioid regulatory framework is revealed as a self-perpetuating model, where restrictive forces at international and national level reinforce negative attitudes and fears of prescribing opioids at sub-national level. • • Data based upon inadequate levels of opioid consumption is then used to estimate opioid requirements for the following year, resulting in a cycle of inadequate opioid availability. • • Global policies must focus upon enabling access to opioids based upon evidence-based assessments of population-level need for opioids. • • Nations should implement legislation affirming governmental responsibility for ensuring access to opioids, to create a positive regulatory context and assuage concerns of clinicians relating to legal redress for prescribing opioids. • • Improved education and training opportunities regarding the benefits of opioids and safe prescribing are essential to challenge negative perceptions of opioids and increase human resources for prescribing and clinical care. in the Preferred Reporting Items for Systematic Reviews (PRISMA) guidelines. 15 Data were subjected to critical interpretive synthesis. International, national and sub-national barriers were organised to develop a conceptual framework of opioid availability. Our approach was selected as an appropriate method of identifying all relevant literature and synthesising qualitative and quantitative findings in to singular thematic categories. We developed a pre-defined inclusion/exclusion criteria] to identify articles relevant to our research aims (Table 1) . A systematic search was conducted in two parts to identify articles ahead of applying the inclusion/exclusion criteria. Originally, we planned to conduct a worldwide review of perceptions and experiences of laws and regulations governing access to opioids. However, during study selection after the initial search, it became apparent that the volume of relevant papers being identified, would not allow analysis with an appropriate level of detail and focus. South, Southeast, East and Central Asia was selected as the amended focus of the review due to several factors. First, a regional focus is consistent with how the INCB reports statistics related to consumption, implying a regional approach to international regulatory oversight. 16 Secondly, South, Southeast, East and Central Asia is the world region with the greatest unmet need for therapeutic opioids and is known to face significant regulatory barriers to their availability. 2 Third, narrowing our focus, allows for models of good or bad practice to be identified, which are likely to have contextual relevance within countries and across the region. 17 Finally, a focus on Asia allows incorporation of data from low, middle and high income countries. We excluded papers focussed upon countries in the Middle East and Western Asia and the Caucasus, due to particular political challenges in the delivery of healthcare in these regions. Following these changes during a period of reflection, an updated search was performed on 20th May 2019 by an experienced information specialist which repeated the initial search strategy for all databases but in addition, added in a fourth concept of South, Southeast, East and Central Asia as well as limiting the results to those published since the previous search. Search terms for Asia included the "exploded" indexed term for Asia for respective databases as well as a text word search for individual countries for example, China or India. Although countries in the Middle Literature reporting perceptions and experiences of laws and regulations governing access to opioids in terms of one or more of the following: • Access to opioid therapeutics • Barriers to opioid availability and accessibility • Facilitators to opioid access 6. Literature fulfilling above criteria pertaining to one or more of the following: • Health system factors • Policy -international, national, regional or local • Legislation -international, national, regional or local • Models of care including availability, logistical organisation and delivery 1. Conference abstracts, case studies, case reviews, reviews, systematic reviews, nonpeer reviewed literature, grey Literature 2. Studies reporting data not pertaining to opioids for pain relief -such as those related to opioid dependence or withdrawal 3. Studies reporting data pertaining to individual clinical practice including patient characteristics, physician decision making and medication efficacy • Amongst those who do not have the licence, many respondents (60.66%) attribute this to the fact that their hospitals do not provide them with the necessary S2 licence and yellow prescription form even when they are in government practice 9 Khan et al. 28 The objective of the study was to gather pertinent Bangladeshi information to assist health professionals, policy makers and the community in the development of programs to improve the care of patients with moderate to severe pain Cross-sectional (survey) 32 To provide up-to-date worldwide, regional, and national data for changes in opioid analgesic use, and to analyse the relation of impediments to use of these medicines Cross-sectional (survey) 214 countries Worldwide, regional, and national study (Asian data extracted) • Study reports impediments to the availability of opioid analgesics in East and Southeast Asia as: "Absence of awareness or training in use of opioid drugs in members of the medical profession" 3 (33%), "Restricted financial resources" 5 (56%), "Issues in sourcing from industry or imports" 3 (33%), "Fear of diversion to illicit channels" 6 (67%), "Control measures applicable to international trade such as need for import or export authorisation" 1 (11%), "Fear of criminal prosecution or sanction" 3 (33%), and "Onerous regulatory framework for prescription of narcotic drugs for medical use" 1 (11%) 14 Vijayan et al. 33 To obtain a clearer picture of the current role and clinical use of Tramadol in Southeast Asia Pain specialists from seven countries in the region were invited to participate in a survey of their individual use and experience of Tramadol Southeast Asia • Respondents from India, Indonesia and Pakistan also stated that there is limited or no availability of controlled opioid analgesics in their countries • Every one of the respondents considered tramadol to be either significant or highly significant in the treatment of moderate to severe non-cancer pain in their home country, specifically mentioning acute indications such as labour pain, postoperative and post-traumatic pain, and chronic indications such as low back pain and osteoarthritis • Respondents strongly agreed that tighter regulation would lead to a significant reduction in the medical availability of tramadol, especially in the outpatient setting • In total, 72% of responders (33 of 46 countries) expressed concern that the introduction of control measures would limit accessibility to tramadol and make doctors more reluctant to prescribe it 15 Singh et al. 34 To assess current knowledge, attitude, prescribing practices, and barriers perceived by the Indian medical practitioners in three tertiary care hospitals towards the use of opioid analgesics Cross-sectional (survey) Sample size: 308 medical practitioners at three tertiary hospitals in New Delhi • Two-thirds of the participants (61.7%) reported that they had never received any formal training in pain management, whilst 38.5% of the participants had • Seventy-eight percent (78.6%) of the participants reported that they had never faced any unwanted attention from the authorities as a result of prescribing opioids • Those who felt that addiction potential was a barrier to prescribing opioid analgesics were not more likely to report that they have not received adequate training in pain management Studies were included if they met our inclusion criteria and did not meet our exclusion criteria (Table 1) . Following the described changes to our research aim and search strategy, included articles must be focussed on South, Southeast, East and Central Asia, or have extractable data relevant to these regions. Two authors independently screened study titles and abstracts identified by the searches against the inclusion/ exclusion criteria. Full texts of studies were retrieved where necessary to assess eligibility. If a study was rejected at full text review, a reason for exclusion is reported. Disagreements were resolved through consensus, with the involvement of a third author. We included a further eligible study published outside of our search period which we only became aware of a further eligible study during background research for manuscript drafting published outside of our search period which we included. Data extraction forms were developed to extract quantitative, qualitative and mixed-methods studies. Two authors independently extracted data from each included paper regarding study aims, national setting, study design and key findings relevant to the aims of our review. Combined data extraction is presented in Supplementary File 2. Extracted data informed analysis and individually extracted studies were referred to at the conclusion of theme development and data synthesis, to ensure that analysis accurately reflected extracted data. Quality appraisal was undertaken using the Mixed Methods Appraisal Tool (MMAT), 2018 tool, which is appropriate for appraising qualitative, quantitative and mixed methods studies. 18 Appraisal was conducted in line with guidance for using the MMAT by two researchers; disagreements were resolved through discussions with a third researcher. The purpose of the MMAT is to gain an impression of overall methodological quality and it is discouraged to calculate a quality score for studies. The purpose of our appraisal was therefore not to develop individual scores for included studies, but to identify methodological issues that should be taken into consideration during interpretation. We conducted a critical interpretive synthesis of included studies, incorporating key processes recommended by Dixon et al. 19 We refined our research question following initial searching, to focus specifically upon factors influencing opioid availability in South, Southeast, East and Central Asia, as the world region most likely to have challenges providing safe opioid access and availability to its population. Quantitative and qualitative data were extracted to a piloted extraction form in Microsoft Word v.16.0, 2016 by two researchers (JC, SG a ). Data were then coded iteratively and organised in thematic areas (JC, SG a ). Preliminary themes were then developed and reviewed, with further sub-themes were defined (JC, SG a , MJ). Data were synthesised within emergent themes using quantitative data with supporting qualitative data to develop analytic themes. A reflective analytical draft of results (JC) was drafted to produce a synthesised argument based upon findings extracted from included studies. This draft was reviewed by the study team and appropriate re-organisation of primary themes was undertaken, responsive to concerns and in the context of quality of included studies. As some data may be considered relevant to more than one theme, further minor modifications were made to developed themes during manuscript preparation in accordance with interpretive synthesis guidelines to use ongoing critical orientation. 18 Following data synthesis, identified barriers were organised into international and sub-national levels to develop a conceptual framework of barriers to opioid availability in South, Southeast, East and Central Asia. We included a broad range of evidence to inform our emergent theory to ensure this was critically informed and plausible given the available evidence. Over the two searches, 11,085 results were retrieved after deduplication, 10706 from the initial search [2017] and 379 from the more focussed update search [2019]) ( Figure 1) . We identified 11086 potentially relevant studies. After study selection, 21 studies met our inclusion criteria: quantitative (n = 15), qualitative (n = 3) and mixed-methods (n = 3). Most included were internationally focussed (n = 9), other studies came from India (n = 4), Thailand (n = 3), Bangladesh (n = 2), China (n = 1), Pakistan (n = 1) and the Philippines (n = 1). Characteristics and key findings of included studies are reported in Table 2 . The quality of studies varied. Key issues identified with the quantitative studies related to poor justification of sample sizes and reporting of non-responders, making conclusions regarding the representativeness of findings difficult to draw. Quality of qualitative studies was mixed. Instances of poor reporting of methods, particularly relating to data collection methods, made overall quality difficult to appraise. Mixed-methods studies were generally of high quality, although, limited reporting made it difficult to assess whether the different components of the studies adhered to quality criteria of each tradition of the methods involved. Overall, study quality made potential bias within studies difficult to assess. Critical integrative synthesis 18 led to the development of a model of overarching domains and sub-themes. Our model of key determinants (Table 3 ) encompassed four domains with 10 sub-themes. In the text below, we report a synthesis of qualitative and quantitative findings. Supporting quantitative and qualitative data were selected to illustrate concepts represented. This domain incorporates factors at international and national levels perceived to influence opioid availability in Asian countries. There is limited evidence that nations in Asia acknowledge legal responsibility for enabling access to opioids as an essential aspect of healthcare. As part of an international review into drug laws, none of the included Asian countries had laws which established the government's responsibility to ensure adequate provision of opioid drugs for medical and scientific purposes. 37 No qualitative studies elicited views on legal, regulatory and socio-political factors affecting access to opioids. Participants within an Asia-wide survey identifying factors affecting opioid availability report control measures applicable to international trade, such as need for import or export authorisations, as barriers in six countries in west and south Asia. Respondents in a survey into the use of Tramadol in southeast Asia, strongly agreed that tighter regulation would lead to a significant reduction in the medical availability of Tramadol, raising particular concerns about subsequent lack of appropriate medication for cancer pain. 32 Historically, in India, physicians reported how a law in 1985 which aimed to quell abuse and trafficking of narcotics was responsible for the medical profession becoming hesitant to use Morphine and, in the months and years following the law, pharmacies all over the country stopped stocking Morphine. 39 This law was superseded in 2014 by the Narcotic Drugs and Psychotropic Substances Amendment Bill which aimed to reduce bureaucracy to ensure continuity of supply of opioids. However, in spite of this, a recent survey of clinicians found that 61% of clinicians had concerns about administrative burden and 56% feared possible scrutiny of records by regulating bodies or law enforcement agencies for prescribing opioids. 33 Another cross-sectional study found that over half the country reporters identified "negative language in existing drug laws" and half had laws forbidding driving whilst on opioids. 23 Countries which have greater integration of palliative care in to the health system reported that higher opioid usage and the extent of government expenditure on healthcare predicted opioid usage. 25 In a comparative study, US respondents were twice as likely as Japanese physicians to indicate that opioid treatment was a legal expectation. 21 Whilst no Asian country has laws which prohibit opioid availability, a lack of legal obligation to enable access to opioids creates a regulatory climate where clinicians may fear criminal accountability for misprescribing. A cross-sectional study in China, found that 62.8% of clinicians had concerns about regulatory investigation for prescribing opioids. 30 In the context of the barriers identified above, opioid availability refers to permitted opioid formulations as well as issues relating to continuity of supply. Contradictory findings were identified, with different studies affirming and denying the availability of opioids, particularly Morphine, in Asian countries. In Thailand, Codeine and Morphine were reported as the most commonly available drugs, whilst an Asia-wide study reported that Tramadol is commonly the only strong analgesic available for treating cancer pain. 32 Seven countries (Afghanistan, Bangladesh, Bhutan, Cambodia, Kazakhstan and Laos) were identified by a cross-sectional study as not having oral immediate release (IR) Morphine available. 23 Many included studies identified issues related to availability in terms of continuity of supply. In Thailand, limits are set on the amount prescribed by health insurance types and the amount of oral opioids in the pharmacy's stock. 24 Issues in sourcing from industry or imports 3 (33% participants) in east and southeast, 6 (29%) in south and west reported as barriers in a cross-sectional survey as barriers to continuity of supply. In this context, clinicians report serious problems treating their patients. Opioid accessibility refers to practical factors influencing access to opioids when opioids are technically available within a country. Several included studies report bureaucratic barriers to accessing opioids, at national policy level and due to hospital pharmacies at local level, with onerous regulatory frameworks for prescription of opioids reported across Asia. 31 For example, an ethnographic study of a cancer hospital in South India reports the difficulties of accessing opioids, even when they are technically available within a pharmacy: "Right now, it [Morphine] has come, but the Drug Inspector has to come and open [the package] and then we will distribute. Today is the 3rd day, Friday, Saturday, and Monday; 3 days' gap. Patients came. I told to the patients, "wait till Monday or you can take weak opioid. . . and you can take steroid . . . and then we will write for Voveran (diclofenac) and Rantac (ranitidine)". . . Sometimes, they beg from other people that are rich in their family, because, [they say] 'without this tablet, I cannot reduce my pain, I can't reduce my breathlessness, I can't reduce my cough'." [palliative care nurse, India (p519)] 34 In spite of low cost options, the cost of opioids was identified as a barrier to access in several studies. In China, 16.5% of clinicians reported patient inability to pay for analgesics as a barrier. 30 A review of the affordability of opioids found a negative correlation between a days' wages and the country income category: the lower the income, the more working days required to pay for the treatment. 22 Patients paid the full cost of all medications in Bangladesh, Cambodia, Indonesia, Laos, Nepal and the Philippines. 23 This revealed inequities in access in Bangladesh, whereby more affluent patients are able to afford expensive formulations such as fentanyl transdermal patches, whilst more deprived patients struggled to pay for any opioid. 37 Permitted prescribing centres identified by this review were commonly cancer centres, in urban areas. Evidence suggests practical challenges of travel to prescribing centres as barriers to opioid accessibility: "Morphine is more available at South India Cancer Hospital (SICH) than most of India. . . The typical patient was financially destitute, illiterate, suffering from metastatic disease, and had travelled hundreds of kilometres to seek care." [field observation, research ethnographer, India (p517)] 34 "They want access to health care which is very difficult in our country, because the national cancer Hospital is in Dhaka. There are not well organised places in other hospitals . . .It's again a bit of financial constraint that causes the problem because they can't travel so much and we cannot go to them." [S3, Physician, Bangladesh (p6)] 37 Even when technically available and accessible from pharmacies further barriers were faced by clinicians to prescribing opioids. Several Asian countries require physicians and other clinicians to have a special authority/licence to prescribe opioids. 23 Cambodia, China, Laos, Mongolia, Myanmar, Pakistan, the Philippines and Thailand had restrictive access to these forms, whilst Cambodia, Mongolia, Pakistan and the Philippines required payment for these prescription forms. 23 In spite of such regulatory precaution, in Bangladesh this does not ensure patients and adequate supply of medicine and limitations are commonly placed upon prescriptions: 24 "Availability is an issue . . . we do have to put our seal and our name and registration number and send it. Patients need, say, for one month-if they need thirty, they are given ten." [S3, Physician, Bangladesh (p5)] 37 Nurses are allowed to prescribe with special authority in Bhutan and the Philippines, and in emergency situations in Afghanistan, and are particularly identified as an enabler of access in Thailand. Yet, only ten community hospitals in Thailand (out of 257 hospitals overall) permitted nurse prescribing. In India in particular, availability of clinician and nurse human resources was reported as a barrier to pain management: With rare exception, Morphine (oral and intravenous) was prescribed exclusively by two or three physicians in the palliative care outpatient clinic [field observation, research ethnographer, India (p517)]. 34 In part, the nurses' lack of engagement with pain assessment and management related to nurse-to-patient ratios that sometimes exceeded 1 nurse for more than 60 patients, negating the ability to provide individualized care [field observation, research ethnographer, India (p518)]. 34 In South India, access to Morphine was said to be largely limited to patients seen by the palliative care service (20% of total patients). 34 Another study in India found that only 61% of clinicians within the study felt that it is appropriate both legally and clinically to prescribe opioids in acute pain due to trauma. 33 In Thailand, for palliative care patients who could not go to the hospital due to poor physical status, caregivers were permitted to obtain opioids on behalf of patients in nearly 80% of hospitals. However, models of emergency prescribing (defined as one when there is an immediate need for relieving strong cancer pain but the physician is not able to physically provide a prescription) were scarce across Asia. Only five states allowed emergency prescribing by fax or phone, namely Bhutan, Indonesia, Laos, Malaysia and Pakistan. 23 In Thailand, limits are set on the amount (of Morphine) prescribed by health insurance types and the amount of oral opioids in the pharmacy's stock. 29 Across many studies, negative attitudes, concerns and knowledge of prescribers limited provision of opioid medications. In India, "Some nurses felt that even Morphine was ineffective in treating cancer pain, as they viewed opioid side effects as offsetting any benefit" 34 and in spite of pain management provided by palliative care services, uptake was commonly limited due to patients' negative perceptions of palliative care. Negative attitudes are perhaps associated with a lack of knowledge of the benefits of opioids. One study of 300 physicians and 58 policymakers/regulators reported that 62.1% of physicians and 74.5% of policymakers/regulators had inadequate knowledge of the benefits of opioids for cancer pain and lack of training opportunities were perceived as a barrier to opioid availability. 24 Finally, in spite of positive initiatives to enable provision in Thailand, clinicians report personal concerns: "Prescribing Morphine to be used at home is new for this District Health Service (DHS). I am concerned about the drug abuse; therefore, this DHS does not prescribe Morphine to be used in the community/at home. We need to set a guideline first." [PHAR1 (p343)] 40 Clinical guidelines for pain relief are reported within included studies as enablers of access to opioids. In the Philippines, a survey of clinicians found that 72% were aware of the WHO Ladder for Pain Control. 26 In South Asia more generally, the inclusion of Tramadol on step two of the WHO ladder, as an enabler of access to pain relief. However, a study from Bangladesh reported frustration that Tramadol was the only available option, reporting: We are compensating with various other drugs for stage two, three . . . of the [WHO] step ladder. We cannot get sufficient Morphine [Medical Director, Bangladesh (p5)]. 37 Our study is the first to systematically review evidence of enablers and barriers of access to opioids in South, Southeast, East and Central Asia and how these manifest in practice. Our review highlights how legal, regulatory and socio-political actions intended to enable availability of opioids, unintentionally limit availability and practical access to opioids within countries. We demonstrate how barriers at international, national and sub-national levels, interact to limit opioid availability, opioid accessibility and potential for appropriate prescribing of opioids. The consequence of these interrelated factors is inadequate supply and consumption of opioids, resulting in avoidable patient suffering. Of concern, inadequate consumption at sub-national levels due to identified barriers, provides data to inform estimates of future requirements for opioids at national level, for submission to international level (INCB). Thus, a self-reinforcing model of inadequate opioid availability and consumption is perpetuated (Figure 2) . We structure our discussion in terms of key messages for stakeholders at international, national and national levels in context of thematic findings. There is evidence that international and national laws foster a policy environment, where opioids are technically permitted, but access is not positively enabled for patients in need. International drug law aims to ensure balance in national policies on controlled substances in terms of availability and accessibility of controlled medicines. Although all Asian countries are signatories of the Single Convention on Narcotics, few Asian countries have laws specifically noting governments' obligations to enable access to controlled substances for medical and scientific purposes. Along with "negative language" reported in laws, such factors may explain findings relating to clinicians fearing legal repercussions from prescribing opioids, as opposed to feeling a legal expectation to do so within clinical guidelines. National lawmakers should legislate to acknowledge governmental obligation to ensure safe access to controlled substances. This would be consistent with the aims of the Single Convention and may help allay clinician concerns regarding redress for prescribing opioids and promote appropriate access. A lack of continuous supply of opioids combines issues relating to availability and accessibility. Sourcing from industry and issues relating to importing opioids were reported as barriers to adequacy of supply. Health systems across Asia should consider streamlining bureaucratic processes aimed at increasing safety of opioid regulations, which paradoxically limit availability and cause patient suffering. India for example, passed the Narcotic Drugs and Psychotropic Substances Amendment Bill, 2014 aimed at reducing bureaucracy to ensure continuity of supply of opioids, although the practical effects of this law are yet to be evaluated. 41 All nations in Asia should ensure that bureaucratic processes enable, rather than limit, continuity of supply of opioids. Increased education and training opportunities for regulators, and clinicians are also required, to both change negative perceptions of opioids and increase human resources for prescribing. The finding that Codeine and Tramadol were the most readily available opioids supports suggestions that layers of legal and regulatory process are removed for substances not under international control. Clinicians, who use Tramadol as part of WHO guidelines appear to be justified in their concerns that greater regulation may limit practical access to Tramadol and remove their only appropriate medication for cancer pain relief. This is supported by a survey conducted by the INCB itself which confirmed the negative impact of an international scheduling on the availability of Tramadol. In total, 72% of responders (33 of 46 countries) expressed concern that the introduction of control measures would limit accessibility to Tramadol and make doctors more reluctant to prescribe it. 42 Yet, there are ongoing reports that due to misuse and abuse of Tramadol due to over-availability in Asia, the International Narcotics Control Board is still currently reviewing whether to bring Tramadol under international control. 43 Doing so would make Tramadol subject to many of the structural barriers to accessible medicines identified by this review and limit the availability of the only practical pain medication currently available to many clinicians in Asia. In circumstances where appropriate prescribing is possible, patients across Asia face further barriers to accessing opioids due to barriers imposed by health services and the cost of medicine. Opioids are currently less affordable in Asia than in western countries. 28 International and national regulators have an obligation to ensure that essential opioids are made available at an affordable price in accordance with the Trade-Related Aspects of Intellectual Property Rights (the TRIPS Agreement) to make it easier for poorer countries to obtain cheaper generic versions of patented medicines. 44 In particular, low-cost formulations, (e.g. oral Morphine) should be prioritised to ensure that cost does not limit the prospects of patients in medical need of pain relief. Health facilities licensed to prescribe opioids are scarce across Asia, presenting logistical challenges to seriously ill patients in presenting at an appropriate centre. Wellfunctioning opioid prescribing centres were identified by this review, commonly Cancer Hospitals and palliative care centres. However, such centres are commonly centralised around urban areas. Coverage of prescribing centres should be prioritised as a key aspect of efforts to achieve Universal Health Coverage in line with nations' commitments to the Sustainable Development Goals. One approach to doing this would be to identify locally appropriate, safe and effective prescribing models in the Asian context, and considering how such models may be transferrable to other settings, to promote opioid availability and accessibility, outside of urban centres. Our review found evidence from Asia suggesting that a lack of human resources for prescribing is a key barrier to opioids availability. It is also of concern that we identified reluctance amongst clinicians to prescribe for medical problems (e.g. trauma), not accounted for by the WHO pain ladder. 33 Opioid training courses are available across Asia, and physicians at all levels of health systems should be encouraged to attend. However, it should be noted that most training courses are for the purpose of prescribing opioids for cancer pain only, and programs are urgently required which teach appropriate prescribing for other conditions that opioids are indicated for, e.g. trauma. When opioid treatments do reach hospital pharmacies, a further layer of bureaucratic and regulatory delays limit the chances of patients with legitimate need from receiving appropriate treatment. Our review also found evidence that due to shortages of medicines, patients legitimately prescribed opioids do not receive their full prescriptions, leading to inadequate dosing. Furthermore, regulations which do not permit pharmacists to correct errors on prescriptions, create a further potential barrier to patients receiving their opioid prescriptions, even when they are technically "available." Other Asian nations may consider following the example of Thailand, which has removed this layer of bureaucracy for patients with a legitimate prescriptions, with minor completion errors (e.g. a spelling mistake). Health systems should further consider enabling nurse-prescribing of opioids, which was identified as an enabler of access in Thailand as part of a strategy to improve the coverage of opioid prescribing to enhance availability and reduce logistical challenges faced by patients in need of opioid treatments. Since our analysis was conducted, the COVID-19 pandemic has increased morbidity and need for opioids in Asia. 45 In response, the INCB has encouraged governments worldwide to avail of flexibility within their regulations in the context of acute emergencies, which allow simplified control procedures for the export, transportation and supply of medicinal products containing controlled substances. 46 We endorse the leadership from the INCB in this regard. However, it remains unclear whether Asian governments will utilise this flexibility to meet the need for opioids of COVID-19 patients. Additionally, this approach would appear to place the emerging needs of COVID-19 patients ahead of those with more predictable needs for opioids. Given the legal and regulatory barriers to opioid availability and accessibility identified by our review in context of the estimates system, we reiterate our call for amended international laws and regulations of controlled substances aimed at meeting the needs of all patients who urgently require appropriate pain treatment. Our study reveals how barriers at international level result in overly restrictive laws and regulations at national level. A lack of education amongst policymakers regarding the benefits of opioids allows uncritical continuity an absence of training opportunities and restrictive laws and regulations which limit overall stocks and trades in controlled substances. The consequences of such barriers at international and national level are to reinforce negative perceptions of opioids at sub-national level, leaving an inadequate prescribing workforce, working within a context of bureaucratic barriers. Overall, systemic barriers at international, national and sub-national levels, interact to perpetuate a cycle of inadequate opioid availability and accessibility, leading to inadequate consumption ( Figure 2) . Perversely, data relating to inadequate consumption are then used by nations to estimate their requirements for opioids for the following year for submission to the International Narcotics Control Board, which then places an upper limit on stocks and trades for nations based on inadequate assessments of requirements. International and national leadership is urgently required, to "re-frame" discourse relating to opioids to create a positive obligation to health systems to enable availability and accessibility of opioids. 47 Doing so may help streamline bureaucratic process relating to opioid access and create a positive obligation amongst prescribers to prescribe opioids based on present patient problems, supported by clinical guidelines, not restricted by overly prohibitive drug laws. Finally, access to palliative care was identified as an enabler of access to opioids. This may be accounted for by the tireless advocacy undertaken by many palliative care activists to promote access to palliative care as a basic human right. Worryingly, negative patient perceptions of care are reported as a barriers to accessing palliative care and associated pain treatment. Of further concern, our review identified no evidence regarding access to opioids for purposes other than cancer pain, for example, trauma. Focussed advocacy from health lobbies including, notably, emergency medicine and maternal health, is required to promote access to opioids as a key aspect of good healthcare at all levels of health systems. A key strength of this review is that it uses empirical evidence to highlight how barriers to safe opioid availability at international, national and national levels interact to limit the prospects of patients in need of opioid treatments at sub-national level. By drawing upon empirical evidence of how legal and regulatory barriers manifest at sub-national levels, we identify the inadequacy of global opioid policy, from whence national and sub-national barriers emerge. Our review used robust methods, adheres to standard guidelines, and critically appraises and reviews included studies and the evidence derived. We aimed to locate all available peer reviewed published evidence. We searched six databases including trial registries, however, grey literature was not specifically searched and therefore potentially relevant policy documents may have been missed. However, the focus of our review was on how policies and regulations manifest in practice based upon research evidence. A weakness of the study is that we included English language papers only, due to resource constraints, therefore studies published in local languages which may have been relevant have not been identified or included. However, from our search strategy, no studies were excluded for language reasons and studies from Asiabased journals are included. Included studies were also of mixed quality, the conclusions of our review should therefore be interpreted in the context of varying quality of evidence identified. Finally, most included papers related to South Asia, Southeast and East Asia with only a few identified and included from Central Asia. Our conclusions reflect composite findings from available evidence, but we would recommend studies to be further studies conducted in Central Asia to identify legal and regulatory barriers. We would also encourage researchers to adopt our methods to conduct analyses of other world regions. Legal and regulatory barriers at international, national and sub-national levels create and reinforce a system of inadequate availability and accessibility of opioids in Asia. The Single Convention on Narcotics imposes a mandate to restrict access to opioids on national governments and contributes to negative perceptions of the benefits of opioids. However, after 60 years of the Single Convention, national drug laws and regulations appear overly restrictive. Education on the benefits of opioids is urgently needed at national and sub-national levels, to reduce negative attitudes and increase human resources for prescribing. However, global policy reform is urgently required to end the cycle of inadequate availability of opioids which is endemic across Asia. Availability and utilization of opioids for pain management: global issues Alleviating the access abyss in palliative care and pain relief-an imperative of universal health coverage: the Lancet Commission report World Health Organization. WHO's cancer pain ladder for adults The global burden of musculoskeletal pain-where to from here? Trauma and acute care surgeons report prescribing less opioids over time Postoperative pulmonary complications Opioids for chronic refractory breathlessness: right patient, right route? What is the value of palliative care provision in low-resource settings? Palliative care as an international human right Does the International Narcotics Control Board (INCB) sufficiently prioritise enablement of access to therapeutic opioids? A systematic critical analysis of six INCB annual reports Launch of the 2019 annual report of the International Narcotics Control Board (INCB) CRD's guidance for undertaking reviews in health care. Centre for reviews and dissemination Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement International Narcotics Control Board. Report of the International Narcotics Control Board for 2019 International palliative care research in the context of global development: a systematic mapping review Mixed Methods Appraisal Tool (MMAT), version 2018. Registration of Copyright (#1148552). Canadian Intellectual Property Office Conducting a critical interpretive synthesis of the literature on access to healthcare by vulnerable groups Adequacy of opioid analgesic consumption at country, global, and regional levels in 2010, its relationship with development level, and changes compared with Adequacy of pain control in patients with advanced cancer in Pakistan Comparison of opioid prescribing patterns in the United States and Japan: primary care physicians' attitudes and perceptions Cross-sectional pilot study to monitor the availability, dispensed prices, and affordability of opioids around the globe Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Asia: a report from the Global Opioid Policy Initiative (GOPI) Knowledge, attitudes and barriers of physicians, policy makers/regulators regarding use of opioids for cancer pain management in Thailand Multivariate analysis of countries' government and health-care system influences on opioid availability for cancer pain relief and palliative care: more than a function of human development Opioid use in the Philippines-20 years after the introduction of the WHO analgesic ladder Physicians knowledge and attitude of opioid availability, accessibility and use in pain management in Bangladesh Potent analgesics are more expensive for patients in developing countries Regulation of opioid drugs in Thai government hospitals: Thailand national survey 2012 Special aspects of cancer pain management in a Chinese general hospital Use of and barriers to access to opioid analgesics: a worldwide, regional, and national study Tramadol: a valuable treatment for pain in Southeast Asian countries A cross-sectional webbased survey of medical practitioners in India to assess their knowledge, attitude, prescription practices, and barriers toward opioid analgesic prescriptions An ethnographic study of barriers to cancer pain management and opioid availability in India Do national drug control laws ensure the availability of opioids for medical and scientific purposes? The use of morphine to control pain in advanced cancer: an investigation of clinical usage in Bangladesh Hospice and palliative care development in India: a multimethod review of services and experiences Improving access to opioid analgesics for palliative care in India The development of the community-based palliative care model in a district health system Inside preview of procuring narcotic license International Narcotics Control Board International Drug Policy Consortium. What the INCB June alerts tell us on human rights & Tramadol Access to affordable medicine The key role of palliative care in response to the COVID-19 tsunami of suffering International Narcotics Control Board. INCB, WHO and UNODC statement on access to internationally controlled medicines during COVID-19 pandemic Reframing global palliative care advocacy for the sustainable development goal era: a qualitative study of the views of international palliative care experts The authors would like to thank Lucia Crowther for assistance with quality appraisal of included studies and copy-editing and Professor David Currow, for thoughtful reflections upon our project throughout. Supplemental material for this article is available online. Authors have contributed to the following categories for authorship: (1a) study conception and design: JC, SG, and MJ (1b) acquisition of data: JC, SG, SG, JP (1c) analysis and interpretation of data: JC, SG, JP, LC, MJ, drafting the article: JC, SG, SG, critical revision: all. All authors have approved the final article and agree to be accountable for all aspects of the work. The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. The author(s) received no financial support for the research, authorship, and/or publication of this article.